Q-omics provides the consensus-scored RPSAP48 profile across patient tissues and cancer cell-line models. RPSAP48 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RPSAP48 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, RPSAP48 RNA expression shows 6,439 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, KIRC, and STAD as cancer lineages where RPSAP48 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPSAP48 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPSAP48 survival associations across molecular data types. RPSAP48 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPSAP48 RNA expression–survival associations across cancer types. High RPSAP48 expression shows unfavorable associations in LIHC, BRCA, PAAD, COAD and SKCM, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for RPSAP48 RNA expression.
This table summarizes RPSAP48 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPSAP48. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPSAP48 shows lower tumor expression in THCA and higher tumor expression in KIRC, KIRP and LUAD. The KIRC box plot shows higher RPSAP48 RNA expression in tumor versus normal tissue (log2 FC = +0.069, t-test p < 0.001).
This table shows molecular features associated with RPSAP48 in patient tissues and cancer cell lines. In patient samples, RPSAP48 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
